IP Library Granted Patent US 7,964,648
Granted Patent B2
US 7,964,648 · App. 12/688,038 · Granted Jun 21, 2011

Methods for concomitant administration of colchicine and a second active agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,648
App. No.
12/688,038
Granted
Jun 21, 2011
Kind
B2
Abstract

Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.

Claims (25)

1. A method of treating a patient with colchicine, comprising

orally administering an adjusted daily dosage amount of colchicine to the patient who is receiving concomitant administration of ketoconazole,

wherein the adjusted daily dosage amount of colchicine is 25% to 50% of an intended daily dosage amount of colchicine, and

wherein the intended daily dosage amount of colchicine is a dosage amount suitable for the patient if the patient were not receiving concomitant ketoconazole.

2. The method of claim 1 , wherein the treating is for the prophylaxis of gout flares, and wherein the intended daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant ketoconazole is 0.6 mg twice daily or 0.6 mg once daily.

3. The method of claim 1 , wherein the treating is for acute gout flares, and wherein the intended daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant ketoconazole is 1.2 mg at the first sign of flare, followed by 0.6 mg one hour later, dose to be repeated no earlier than 3 days.

4. The method of claim 1 , wherein the treating is for familial Mediterranean fever

wherein the adjusted daily dosage amount of colchicine is a maximum colchicine dosage amount of 0.6 mg of colchicine per day which is a reduction from the intended daily dosage amount of colchicine in the absence of concomitant ketoconazole wherein the intended daily dosage amount is a maximum daily dosage amount as follows:

Daily dosage amount

Age

Usual

Maximum

Adults and children >12 years

1.2 mg

2.4 mg

Children >6 to 12 years

0.9 mg

1.8 mg

Children 4 to 6 years

0.3 mg

 1.8 mg.

5. The method of claim 2 , wherein the adjusted daily dosage amount of colchicine is 25% of a 0.6 mg twice daily intended dose.

6. The method of claim 2 , wherein the adjusted daily dosage amount of colchicine is 25% of a 0.6 mg once daily intended dose.

7. The method of claim 1 , wherein the concomitantly administered dose of ketoconazole is 200 mg twice per day.

8. The method of claim 3 , wherein the adjusted daily dosage amount is about 50% of the intended daily dosage amount.

Assignments (6)
MERGER Recorded Nov 30, 2012
From: AR HOLDING COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029378/0850 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026700/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2011
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: AR HOLDING COMPANY, INC.
Reel/Frame 026431/0290 →
SECURITY AGREEMENT Recorded Mar 24, 2010
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: UBS AG, STAMFORD BRANCH
Reel/Frame 024133/0300 →